KRAS and gastric cancer: Therefore, we hypothesized that in KRAS mutant gastric cancer cells, the blockade of both PI3K/AKT/mTOR and KRAS/mTOR/STAT pathways using NVP-BKM120 and AG490 would be synergistic.